---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-008711"
form_type: "8-K"
ticker: "SRRK"
cik: "0001727196"
company_name: "Scholar Rock Holding Corp"
filed_at: "2025-06-18T23:59:59+00:00"
generated_at: "2026-05-19T03:11:05.416360+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Scholar Rock Phase 2 EMBRAZE trial shows 54.9% lean mass preservation with apitegromab plus tirzepatide (p=0.001)

## Summary
- Primary endpoint met: apitegromab + tirzepatide preserved 54.9% of lean mass (p=0.001) vs tirzepatide alone over 24 weeks.
- Patients on combination lost 18.8 lbs fat mass vs 17.7 lbs for tirzepatide alone; total weight loss 12.3% vs 13.4%.
- Quality of weight loss improved: 85% fat / 15% lean mass loss with combination vs 70% fat / 30% lean with tirzepatide alone.
- Apitegromab well tolerated; no SAEs or discontinuations related to apitegromab, consistent with prior studies.
- Company plans to file IND for next-gen SRK-439 in H2 2025; conference call today at 8 AM EDT.

## SEC filing metadata
- accession: 0001558370-25-008711
- form_type: 8-K
- ticker: SRRK
- cik: 0001727196
- company_name: Scholar Rock Holding Corp
- filed_at: 2025-06-18T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1727196/000155837025008711/0001558370-25-008711-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1727196/000155837025008711/srrk-20250618x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-008711
- JSON: https://secwatch.observer/filing/0001558370-25-008711.json
- Plain text: https://secwatch.observer/filing/0001558370-25-008711.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.